AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging

🇬🇧 Bloomberg (GB) —

AI Summary

AstraZeneca's shares plunged more than 10% after a rare heart drug trial failed to prevent heart problems in patients. The failure has caused significant market reaction, highlighting the risks in pharmaceutical development.

AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)

Markets Deals Health AI & Tech AstraZeneca drug trial failure shares plunge heart disease pharmaceutical industry

Read original source →